OverviewChartProfileKey statisticsFinancialsTechnicalNewsTraderScreen

BASILEA N/  CH0011432447  /

SIX Swiss Exchange
2024-04-19  5:30:11 PM Chg. -1.200 Volume Bid5:40:00 PM Ask5:40:00 PM Market Capitalization Dividend Y. P/E Ratio
40.750CHF -2.86% 38,782
Turnover: 1.59 mill.		 40.600Bid Size: 219 41.200Ask Size: 200 533.82 mill.CHF - 46.84
GlobeNewswire 04-09 Basilea awarded CARB-X grant to develop recently acquired novel class of antibiotics
GlobeNewswire 04-04 Basilea announces US FDA approval of antibiotic ZEVTERA® (ceftobiprole medocaril) for three indicati...
GlobeNewswire 03-11 Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers mile...
GlobeNewswire 02-13 Basilea reports strong 2023 full-year results with profitability significantly above guidance, whils...
GlobeNewswire 01-19 Cresemba® sales in Latin America trigger first sales milestone payment to Basilea
GlobeNewswire 01-15 Basilea announces acquisition of preclinical antibiotics program from Spexis
GlobeNewswire 01-05 Basilea provides portfolio status update
GlobeNewswire 2023-12-11 Basilea announces that FDA approves expanded use of antifungal Cresemba® (isavuconazole) in the Unit...
GlobeNewswire 2023-11-20 Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers thir...
GlobeNewswire 2023-11-13 Basilea announces acquisition of fosmanogepix, a phase-3-ready broad-spectrum antifungal
GlobeNewswire 2023-10-31 Basilea announces exclusive license and option agreement for potential first-in-class clinical-stage...
GlobeNewswire 2023-10-19 Basilea announces acquisition of novel clinical-stage antifungal for treatment of Aspergillus mold i...
GlobeNewswire 2023-10-17 Basilea reports new data for ceftobiprole (Zevtera®) presented at US IDWeek Congress 2023
GlobeNewswire 2023-10-02 Basilea announces FDA acceptance of New Drug Application for antibiotic ceftobiprole
GlobeNewswire 2023-09-28 Basilea announces New England Journal of Medicine publication of phase 3 data on ceftobiprole for th...
GlobeNewswire 2023-08-15 Basilea reports strong revenue and profit growth in first half-year 2023
GlobeNewswire 2022-03-08 Basilea reports preclinical data on anti-cancer activity of novel oncology drug candidate BAL0891 at...
GlobeNewswire 2022-02-15 Basilea to become a leading anti-infectives company backed by strong financial results 2021
GlobeNewswire 2022-01-24 Basilea reports updated interim results for iCCA patients with FGFR2 mutations and amplifications fr...
GlobeNewswire 2022-01-13 Basilea announces approval of antifungal Cresemba® (isavuconazole) for invasive aspergillosis in Chi...
GlobeNewswire 2022-01-11 Basilea announces completion of patient enrolment in phase 3 ERADICATE study investigating ceftobipr...
GlobeNewswire 2022-01-10 Basilea exceeds 2021 financial guidance on preliminary revenue and year-end cash-position
GlobeNewswire 2022-01-07 Strong Cresemba® (isavuconazole) sales by Astellas in the U.S. trigger CHF 15 million sales mileston...
GlobeNewswire 2022-01-06 Basilea reports on portfolio progress made in 2021
GlobeNewswire 2021-12-21 Basilea receives USD 10 million milestone payment related to approval of antifungal Cresemba® (isavu...